Exosomal miR‐222‐3p contributes to castration‐resistant prostate cancer by activating mTOR signaling

Abstract

AbstractDespite the clinical benefits of androgen deprivation therapy, most patients with advanced androgen‐dependent prostate cancer (ADPC) eventually relapse and progress to lethal androgen‐independent prostate cancer (AIPC), also termed castration‐resistant prostate cancer (CRPC). MiRNAs can be packaged into exosomes (Exos) and shuttled between cells. However, the roles and mechanisms of exosomal miRNAs involved in CRPC progression have not yet been fully elucidated. Here, we find that miR‐222‐3p is elevated in AIPC cells, which results in remarkable enhancement of cell proliferation, migration, and invasion ability. Furthermore, Exos released by AIPC cells can be uptaken by ADPC cells, thus acclimating ADPC cells to progressing to more aggressive cell types in vitro and in vivo through exosomal transfer of miR‐222‐3p. Mechanistically, Exos‐miR‐222‐3p promoted ADPC cells transformed to AIPC‐like cells, at least in part, by activating mTOR signaling through targeting MIDN. Our results show that AIPC cells secrete Exos containing miRNA cargo. These cargos can be transferred to ADPC cells through paracrine mechanisms that have a strong impact on cellular functional remodeling. The current work underscores the great therapeutic potential of targeting Exo miRNAs, either as a single agent or combined with androgen receptor pathway inhibitors for CRPC treatment.